Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 101
Filter
2.
Adv Exp Med Biol ; 1269: 295-300, 2021.
Article in English | MEDLINE | ID: mdl-33966233

ABSTRACT

It has been reported that the cardiovascular response in the supine position is different from that in the sitting position. However, there are few reports on the effects of posture on cerebral oxygenation during exercise. Cycling exercises change oxygenated hemoglobin (O2Hb) and deoxygenated hemoglobin (HHb) levels in motor-related areas. Therefore, this study compared O2Hb levels at motor-related areas during recumbent versus supine cycling. Eleven healthy young male performed a 30-min cycling exercise protocol at 50% of the maximal oxygen uptake (VO2 max) in the recumbent and supine positions. Near-infrared spectroscopy (NIRS) was used to measure exercise-induced O2Hb and HHb changes in the right (R-PMA) and left premotor areas (L-PMA), supplementary motor area (SMA), and primary motor cortex (M1). In R-PMA, L-PMA and SMA, the O2Hb obtained during supine cycling was significantly higher than that during recumbent cycling (R-PMA, 0.031 ± 0.01 vs. 0.693 ± 0.01; L-PMA, 0.027 ± 0.01 vs. 0.085 ± 0.013; SMA, 0.041 ± 0.011 vs. 0.076 ± 0.008 mM·cm, recumbent vs. supine position; p < 0.05). These results suggest that supine cycling exercise increases R-PMA, L-PMA, and SMA O2Hb levels in healthy young men.


Subject(s)
Motor Cortex , Exercise , Humans , Male , Motor Cortex/metabolism , Oxygen Consumption , Oxyhemoglobins/metabolism , Spectroscopy, Near-Infrared
3.
J Neurol ; 267(12): 3565-3577, 2020 Dec.
Article in English | MEDLINE | ID: mdl-32623595

ABSTRACT

INTRODUCTION: While monophasic and relapsing forms of myelin oligodendrocyte glycoprotein antibody associated disorders (MOGAD) are increasingly diagnosed world-wide, consensus on management is yet to be developed. OBJECTIVE: To survey the current global clinical practice of clinicians treating MOGAD. METHOD: Neurologists worldwide with expertise in treating MOGAD participated in an online survey (February-April 2019). RESULTS: Fifty-two responses were received (response rate 60.5%) from 86 invited experts, comprising adult (78.8%, 41/52) and paediatric (21.2%, 11/52) neurologists in 22 countries. All treat acute attacks with high dose corticosteroids. If recovery is incomplete, 71.2% (37/52) proceed next to plasma exchange (PE). 45.5% (5/11) of paediatric neurologists use IV immunoglobulin (IVIg) in preference to PE. Following an acute attack, 55.8% (29/52) of respondents typically continue corticosteroids for ≥ 3 months; though less commonly when treating children. After an index event, 60% (31/51) usually start steroid-sparing maintenance therapy (MT); after ≥ 2 attacks 92.3% (48/52) would start MT. Repeat MOG antibody status is used by 52.9% (27/51) to help decide on MT initiation. Commonly used first line MTs in adults are azathioprine (30.8%, 16/52), mycophenolate mofetil (25.0%, 13/52) and rituximab (17.3%, 9/52). In children, IVIg is the preferred first line MT (54.5%; 6/11). Treatment response is monitored by MRI (53.8%; 28/52), optical coherence tomography (23.1%; 12/52) and MOG antibody titres (36.5%; 19/52). Regardless of monitoring results, 25.0% (13/52) would not stop MT. CONCLUSION: Current treatment of MOGAD is highly variable, indicating a need for consensus-based treatment guidelines, while awaiting definitive clinical trials.


Subject(s)
Autoantibodies , Immunoglobulins, Intravenous , Adult , Child , Humans , Immunoglobulins, Intravenous/therapeutic use , Myelin-Oligodendrocyte Glycoprotein , Plasmapheresis , Surveys and Questionnaires
4.
Adv Exp Med Biol ; 977: 233-240, 2017.
Article in English | MEDLINE | ID: mdl-28685451

ABSTRACT

Our previous studies have shown that water immersion (WI) changes sensorimotor processing and cortical excitability in the sensorimotor regions of the brain. The present study examined the site specificity of the brain activation during WI using functional near infrared spectroscopy (fNIRS). Cortical oxyhaemoglobin (O2Hb) levels in the anterior and posterior parts of the supplementary motor area (pre-SMA and SMA), primary motor cortex (M1), primary somatosensory cortex (S1), and posterior parietal cortex (PPC) were recorded using fNIRS (OMM-3000; Shimadzu Co.) before, during, and after WI in nine healthy participants. The cortical O2Hb levels in SMA, M1, S1, and PPC significantly increased during the WI and increased gradually along with the filling of the WI tank. These changes were not seen in the pre-SMA. The results show that WI-induced increases in cortical O2Hb levels are at least somewhat site specific: there was little brain activation in response to somatosensory input in the pre-SMA, but robust activation in other areas.


Subject(s)
Brain Mapping , Cerebral Cortex/metabolism , Immersion , Oxyhemoglobins/metabolism , Adult , Brain Chemistry , Brain Mapping/methods , Cerebral Cortex/chemistry , Humans , Male , Motor Cortex/chemistry , Motor Cortex/metabolism , Organ Specificity , Oxyhemoglobins/analysis , Somatosensory Cortex/chemistry , Somatosensory Cortex/metabolism , Spectroscopy, Near-Infrared/methods , Water , Young Adult
5.
Osteoporos Int ; 28(4): 1481-1490, 2017 04.
Article in English | MEDLINE | ID: mdl-27933339

ABSTRACT

This study showed that bisphosphonate was safe and effective for the treatment of bone disorders in stage 4 chronic kidney disease (CKD) rats. Intermittent teriparatide therapy showed an anabolic action on bone even under secondary hyperparathyroidism conditions without having an adverse effect on mineral metabolism in late-stage CKD. INTRODUCTION: Patients with late-stage CKD are at high risk for fragility fractures. However, there are no consensus on the efficacy and safety of osteoporosis medications for patients with late-stage CKD. In the present study, we aimed to examine the efficacy and safety of alendronate (ALN) and teriparatide (TPD) for treating bone disorder in late-stage CKD with pre-existing secondary hyperparathyroidism using a rat model of CKD. METHODS: Male 10-week-old Sprague-Dawley rats were subjected to a 5/6 nephrectomy or sham surgery and randomized into the following four groups: sham, vehicle (saline subcutaneous (sc) daily), ALN (50 µg/kg sc daily), and TPD (40 µg/kg sc daily). Medications commenced at 24 weeks of age and continued for 4 weeks. Micro-computed tomography, histological analysis, infrared spectroscopic imaging, and serum assays were performed. RESULTS: Nephrectomized rats developed hyperphosphatemia, secondary hyperparathyroidism (SHPT), and high creatinine, equivalent to CKD stage 4 in humans. ALN suppressed the bone turnover and increased the degree of mineralization in cortical bone, resulting in an improvement in the mechanical properties. TPD further increased the bone turnover and significantly increased the degree of mineralization, micro-geometry, and bone volume, resulting in a significant improvement in the mechanical properties. Both ALN and TPD had no adverse effect on renal function and mineral metabolism. CONCLUSIONS: BP is safe and effective for the treatment of bone disorders in stage 4 CKD rats. Intermittent TPD therapy showed an anabolic action on bone even under SHPT conditions without having an adverse effect on mineral metabolism in late-stage CKD.


Subject(s)
Bone Density Conservation Agents/therapeutic use , Hyperparathyroidism, Secondary/complications , Hyperphosphatemia/complications , Osteoporosis/drug therapy , Renal Insufficiency, Chronic/complications , Alendronate/adverse effects , Alendronate/pharmacology , Alendronate/therapeutic use , Animals , Bone Density Conservation Agents/adverse effects , Bone Density Conservation Agents/pharmacology , Bone Remodeling/drug effects , Disease Models, Animal , Drug Evaluation, Preclinical/methods , Femur/diagnostic imaging , Femur/drug effects , Femur/metabolism , Lumbar Vertebrae/diagnostic imaging , Lumbar Vertebrae/drug effects , Male , Nephrectomy , Osteoporosis/diagnostic imaging , Osteoporosis/etiology , Rats, Sprague-Dawley , Teriparatide/pharmacology , X-Ray Microtomography
6.
Osteoporos Int ; 28(2): 709-718, 2017 02.
Article in English | MEDLINE | ID: mdl-27704183

ABSTRACT

This study showed that autoimmune arthritis induces especially severe osteoporosis in the periarticular region adjacent to inflamed joints, suggesting that arthritis increases the fragility fracture risk near inflamed joints, which is frequently observed in patients with RA. INTRODUCTION: Periarticular osteoporosis near inflamed joints is a hallmark of early rheumatoid arthritis (RA). Here we show that rheumatic inflammation deteriorates the bone quality and bone quantity of periarticular bone, thereby decreasing bone strength and toughness in a mouse model of RA. METHODS: Female BALB/c mice and SKG mice, a mutant mouse model of autoimmune arthritis on the BALB/c background, were used. At 12 weeks of age, BALB/c mice underwent either Sham surgery or bilateral ovariectomy (OVX), and SKG mice underwent intraperitoneal injection of mannan to induce arthritis. Eight weeks later, the mice were killed and the femurs and tibias were subjected to micro-computed tomography, Fourier transform infrared (FTIR) spectroscopic imaging, X-ray diffraction, histology, and mechanical testing. RESULTS: SKG mice developed significant trabecular bone loss in both the distal metaphysis of the femur and the lumbar vertebral body, but the extent of the bone loss was more severe in the distal metaphysis. Neither SKG nor OVX mice exhibited changes in the geometry and matrix properties of the diaphysis of the femur, whereas SKG mice, but not OVX mice, did exhibit changes in these properties in the distal metaphysis of the femur. Bone strength and fracture toughness of the distal metaphysis of the tibia adjacent to the inflamed ankle joint were significantly decreased in SKG mice. CONCLUSIONS: Autoimmune arthritis induces periarticular osteoporosis, characterized by deterioration of cortical bone geometry and quality as well as by trabecular bone loss, leading to severe bone fragility in periarticular bone adjacent to inflamed joints.


Subject(s)
Arthritis, Experimental/complications , Arthritis, Rheumatoid/complications , Osteoporosis/etiology , Animals , Arthritis, Experimental/diagnostic imaging , Arthritis, Experimental/physiopathology , Arthritis, Rheumatoid/diagnostic imaging , Arthritis, Rheumatoid/physiopathology , Biomechanical Phenomena , Bone Density/physiology , Bone Resorption/diagnostic imaging , Bone Resorption/etiology , Bone Resorption/physiopathology , Female , Femur/diagnostic imaging , Femur/pathology , Femur/physiopathology , Mice, Inbred BALB C , Mice, Mutant Strains , Osteoporosis/diagnostic imaging , Osteoporosis/pathology , Osteoporosis/physiopathology , Ovariectomy , Severity of Illness Index , X-Ray Microtomography
7.
Drug Res (Stuttg) ; 66(11): 603-606, 2016 Nov.
Article in English | MEDLINE | ID: mdl-27626603

ABSTRACT

Luseogliflozin, a selective inhibitor of sodium glucose co-transporter 2 (SGLT2), was previously shown to improve the blood glucose and hemoglobin A1c (HbA1c) levels of patients with type 2 diabetes in a clinical setting. Although patients with type 2 diabetes often have hepatic impairment, few reports have been published concerning the influence of luseogliflozin on HbA1c and hepatic function in patients with type 2 diabetes accompanied by hepatic impairment. The present study was undertaken to evaluate the influence of luseogliflozin on HbA1c and hepatic function in patients with type 2 diabetes divided into 2 groups according to hepatic function parameters (a normal group and an elevated group). In this study, luseogliflozin significantly improved both HbA1c and body weight to similar extents in both the normal group and the elevated group, accompanied by marked reductions in the aspartate aminotransferase (AST), alanine aminotransferase (ALT), and γ-glutamyl transpeptidase (γ-GTP) levels. These results suggested that luseogliflozin can be safely used in patients with type 2 diabetes who also exhibit hepatic impairment. The results additionally suggest the possibility that luseogliflozin might be capable of alleviating hepatic impairment in patients with type 2 diabetes.


Subject(s)
Diabetes Mellitus, Type 2/complications , Liver Diseases/drug therapy , Liver Diseases/etiology , Sodium-Glucose Transporter 2 Inhibitors , Sorbitol/analogs & derivatives , Asian People , Blood Glucose/drug effects , Body Weight/drug effects , Diabetes Mellitus, Type 2/metabolism , Female , Glycated Hemoglobin/metabolism , Humans , Liver/drug effects , Liver/metabolism , Liver Diseases/metabolism , Liver Function Tests/methods , Male , Retrospective Studies , Sodium-Glucose Transporter 2 , Sorbitol/therapeutic use
8.
Article in English | MEDLINE | ID: mdl-26273732

ABSTRACT

This paper introduces the notion of a reactionless synergy: a postural variation for a specific motion pattern/strategy, whereby the movements of the segments do not alter the force/moment balance at the feet. Given an optimal initial posture in terms of stability, a reactionless synergy can ensure optimality throughout the entire movement. Reactionless synergies are derived via a dynamical model wherein the feet are regarded to be unfixed. Though in contrast with the conventional fixed-feet models, this approach has the advantage of exhibiting the reactions at the feet explicitly. The dynamical model also facilitates a joint-space decomposition scheme yielding two motion components: the reactionless synergy and an orthogonal complement responsible for the dynamical coupling between the feet and the support. Since the reactionless synergy provides the basis (a feedforward control component) for optimal balance control, it may play an important role when evaluating balance abnormalities or when assessing optimality in balance control. We show how to apply the proposed method for analysis of motion capture data obtained from three voluntary movement patterns in the sagittal plane: squat, sway, and forward bend.


Subject(s)
Motion , Postural Balance/physiology , Acceleration , Biomechanical Phenomena , Humans , Male , Movement , Posture/physiology
9.
Drug Res (Stuttg) ; 66(1): 18-22, 2016 Jan.
Article in English | MEDLINE | ID: mdl-26125284

ABSTRACT

It has been reported that dipeptidyl peptidase-4 (DPP-4) inhibitors improve hemoglobin A1c (HbA1c) levels in diabetic patients and may also improve the serum lipids. However, few studies have examined relationship between the effects of the DPP-4 inhibitor and the pretreatment HbA1c levels in diabetic patients. Furthermore, it has been reported that prolonged treatment with DPP-4 inhibitors may make glycemic control difficult in some patients. In the present study, we investigated (1) the effect of the DPP-4 inhibitor alogliptin on HbA1c, blood glucose (BG), and serum lipid in Japanese patients with type 2 diabetes, (2) the relationship between the HbA1c levels at baseline and the effects of alogliptin, and (3) the effects of switching of the DPP-4 inhibitor to alogliptin after 12 months' administration of sitagliptin on glycemic control and serum lipids. After 6-months' treatment with alogliptin, we found reductions of HbA1c, BG, and serum total cholesterol, and LDL cholesterol levels. Pretreatment level of HbA1c was well correlated with the degree of reduction of both HbA1c and BG levels after the treatment. Also, alogliptin kept levels of HbA1c and BG reduced by sitagliptin for 12 months, and relapsing of these levels and serum lipids were not observed. This study revealed that alogliptin improved HbA1c, BG, and serum lipid profiles in type 2 diabetic patients, and the effect of alogliptin on HbA1c and BG levels was correlated with HbA1c level at pretreatment. Furthermore, long-term treatment with alogliptin did not cause relapsing of glycemic control and serum lipids.


Subject(s)
Diabetes Mellitus, Type 2/blood , Diabetes Mellitus, Type 2/metabolism , Dipeptidyl Peptidase 4/metabolism , Dipeptidyl-Peptidase IV Inhibitors/therapeutic use , Glycated Hemoglobin/metabolism , Lipids/blood , Piperidines/therapeutic use , Uracil/analogs & derivatives , Asian People , Blood Glucose/drug effects , Female , Humans , Hypoglycemic Agents/therapeutic use , Male , Middle Aged , Sitagliptin Phosphate/therapeutic use , Uracil/therapeutic use
10.
Mult Scler ; 21(6): 678-88, 2015 May.
Article in English | MEDLINE | ID: mdl-25662342

ABSTRACT

Neuromyelitis optica (NMO) is an inflammatory autoimmune disease of the central nervous system that preferentially targets the optic nerves and spinal cord. The clinical presentation may suggest multiple sclerosis (MS), but a highly specific serum autoantibody against the astrocytic water channel aquaporin-4 present in up to 80% of NMO patients enables distinction from MS. Optic neuritis may occur in either condition resulting in neuro-anatomical retinal changes. Optical coherence tomography (OCT) has become a useful tool for analyzing retinal damage both in MS and NMO. Numerous studies showed that optic neuritis in NMO typically results in more severe retinal nerve fiber layer (RNFL) and ganglion cell layer thinning and more frequent development of microcystic macular edema than in MS. Furthermore, while patients' RNFL thinning also occurs in the absence of optic neuritis in MS, subclinical damage seems to be rare in NMO. Thus, OCT might be useful in differentiating NMO from MS and serve as an outcome parameter in clinical studies.


Subject(s)
Multiple Sclerosis/diagnosis , Neuromyelitis Optica/diagnosis , Optic Neuritis/diagnosis , Retinal Neurons/ultrastructure , Tomography, Optical Coherence/methods , Humans
11.
Drug Res (Stuttg) ; 65(10): 532-4, 2015 Oct.
Article in English | MEDLINE | ID: mdl-25368904

ABSTRACT

Dipeptidyl peptidase-4 (DPP-4) inhibitors have been reported to improve the glycemic control and blood hemoglobin A1c (HbA1c) concentrations. However, there are few reports as yet suggesting that DPP-4 inhibitors may also improve insulin resistance and the serum lipid profile in the clinical setting. This study was aimed at investigating the effect of 14-week treatment with teneligliptin (20 mg/day) on the homeostasis model assessment ratio (HOMA-R), an indicator of insulin resistance, and serum lipid profile in 9 patients with type 2 diabetes. The treatment produced a significant decrease of the blood glucose and HbA1c concentration (blood glucose: p=0.008; HbA1c: p=0.038), and also improved HOMA-R (p=0.039). Furthermore, the patients showed elevation of the serum HDL-cholesterol level (p=0.032), and a tendency towards reduction of the serum triglyceride level. The results indicate that teneligliptin acts not only to improve the blood glucose control, but also to improve the insulin resistance and serum lipid profile in Japanese type 2 diabetes patients.


Subject(s)
Diabetes Mellitus, Type 2/drug therapy , Insulin Resistance , Lipids/blood , Pyrazoles/pharmacology , Thiazolidines/pharmacology , Aged , Asian People , Blood Glucose/drug effects , Diabetes Mellitus, Type 2/blood , Dipeptidyl-Peptidase IV Inhibitors/pharmacology , Dipeptidyl-Peptidase IV Inhibitors/therapeutic use , Female , Glycated Hemoglobin/metabolism , Humans , Hypoglycemic Agents/pharmacology , Male , Middle Aged , Prospective Studies , Pyrazoles/therapeutic use , Thiazolidines/therapeutic use , Treatment Outcome
12.
Zygote ; 23(3): 352-9, 2015 Jun.
Article in English | MEDLINE | ID: mdl-24355610

ABSTRACT

The aim of the present study was to examine the effects of brilliant cresyl blue (BCB) staining on mitochondrial functions in porcine oocytes. Cumulus-oocyte complexes (COCs) collected from slaughterhouse-derived porcine ovaries were cultured with (13 µM) or without (0 µM, control) BCB for 60 min. Mitochondrial functions in oocytes were examined immediately after staining or after in vitro maturation. The BCB-stained oocytes produced reactive oxygen species (ROS) at higher levels than control oocytes immediately after staining (2.2-fold, P < 0.001) and after maturation (1.7-fold, P < 0.001). The adenosine triphosphate (ATP) content and mitochondrial membrane potential (MMP) in oocytes were similar for the two groups immediately after staining. However, ATP and relative MMP levels were significantly (P < 0.05) lower in BCB-treated oocytes than in the control (2.18 versus 2.83 pM and 0.82 versus 1.0, respectively). There was no difference in mitochondrial DNA copy number between the two groups after maturation. The ATP content in early developmental stage embryos (3 days after parthenogenetic activation) was lower in the BCB-stained group than that in the control group but the difference was not significant. In conclusion, BCB staining of oocytes at the immature stage compromises mitochondrial functions throughout oocyte maturation, but function is restored during early embryo development.


Subject(s)
Mitochondria/drug effects , Mitochondria/metabolism , Oocytes/metabolism , Oxazines/pharmacology , Staining and Labeling/methods , Adenosine Triphosphate/metabolism , Animals , Chromatin/metabolism , DNA, Mitochondrial/metabolism , Female , Membrane Potential, Mitochondrial/drug effects , Oocytes/chemistry , Oocytes/drug effects , Reactive Oxygen Species/metabolism , Sus scrofa
13.
Article in English | MEDLINE | ID: mdl-24111164

ABSTRACT

Based on the experimental data of the contraction ratio of fibroblast-collagen gels with different initial collagen concentrations and cell numbers, we analyzed the traction force exerted by individual cells through a novel elementary structural model. We postulate that the mechanical mechanism of the gel contraction is mainly because that populated cells apply traction force to some of the surrounding collagen fibrils with such proper length potential to be pulled straight so as to be able to sustain the traction force; this traction induce the cells moving closely to each other and consequently compact the fibrillar network; the bending force of the fibrils in turn resists the movement. By employing fiber packing theory for random fibrillar networks and network alteration theory, the bending force of collagen fibrils was deduced. The traction force exerted by individual fibroblasts in the gels was balanced by the bending force and the resistance from interstitial fluid since inertial force can be neglected. The maximum traction force per cell under free floating condition is in the range of 0.27-9.02 nN depending on the initial collagen concentration and populated cell number. The most important outcome of this study is that the traction force of individual cells dynamically varies under different gel conditions, whereas the adhesion force between cell and individual fibrils is relatively converging and stable.


Subject(s)
Collagen/pharmacology , Fibroblasts/cytology , Gels/pharmacology , Models, Theoretical , Adhesiveness/drug effects , Animals , Biomechanical Phenomena/drug effects , Cell Count , Cells, Cultured , Collagen/ultrastructure , Fibroblasts/drug effects , Rats, Wistar
14.
Exp Clin Endocrinol Diabetes ; 121(10): 624-7, 2013 Nov.
Article in English | MEDLINE | ID: mdl-24002894

ABSTRACT

In recent years, the number of patients with type 2 diabetes mellitus caused by insulin resistance has continued to increase in Japan. Insulin resistance is considered to be closely related to the risk of cardiovascular diseases and atherosclerotic diseases, represented by arteriosclerosis obliterans (ASO). Therefore, improvement of insulin resistance is one of the important strategies in the treatment of type 2 diabetes mellitus. At present, α-glucosidase inhibitors, incretin-related drugs, and thiazolidinediones are among the most important oral hypoglycemic drugs used to improve insulin resistance. In this study, the effect of beraprost sodium, a prostaglandin I2 derivative, in the treatment of type 2 diabetes mellitus was investigated. In type 2 diabetic patients with ASO who were under treatment with pioglitazone, additional treatment with beraprost sodium exerted a significant synergistic effect in reducing the serum HbA1c levels as compared to treatment with pioglitazone alone. This result indicates that concomitant administration of pioglitazone and beraprost sodium may be useful in the treatment of diabetes -mellitus.


Subject(s)
Blood Glucose/metabolism , Diabetes Mellitus, Type 2/blood , Diabetes Mellitus, Type 2/drug therapy , Epoprostenol/analogs & derivatives , Hypoglycemic Agents/administration & dosage , Thiazolidinediones/administration & dosage , Aged , Drug Therapy, Combination , Epoprostenol/administration & dosage , Female , Humans , Male , Middle Aged , Pioglitazone , Platelet Aggregation Inhibitors
15.
Eur J Vasc Endovasc Surg ; 44(1): 73-6, 2012 Jul.
Article in English | MEDLINE | ID: mdl-22546640

ABSTRACT

OBJECTIVES: Sclerotherapy is useful for the treatment of arteriovenous vascular malformations. However, intravascular administration of sclerotic agents into small arteriovenous niduses is often difficult. Extravascular administration of sclerotic agents causes reduction of vascular flow on Doppler echo during clinical sclerotherapy. Therefore, we aimed to investigate whether the extravascular injection of sclerotic agents affects tiny vessels. DESIGN: Animal study. MATERIALS: The effect of extravascular injection of sclerotic agents on vessels was investigated using rat femoral and superficial inferior epigastric vessels. METHODS: After surgical exposure of vessels, absolute ethanol, 5% ethanolamine oleate and 3% polidocanol were injected into perivascular surrounding tissues, and their effect on vessels was evaluated after 14 days using histology and coloured silicone rubber injection. RESULTS: The integrity of the vascular lumen, endothelial cells and vascular patency were not affected by injection of sclerotic agents. CONCLUSIONS: Attenuation of vascular flow of an arteriovenous shunt after extravascular injection of sclerotic agents is transient and/or trivial and does not cause disruption of vessels. Therefore, sclerotic agents should be delivered to obtain sufficient destruction of arteriovenous malformation lesions and blood flow.


Subject(s)
Arteriovenous Malformations/therapy , Epigastric Arteries/drug effects , Femoral Artery/drug effects , Femoral Vein/drug effects , Sclerosing Solutions/administration & dosage , Sclerotherapy/methods , Animals , Disease Models, Animal , Endothelium, Vascular/drug effects , Endothelium, Vascular/pathology , Epigastric Arteries/abnormalities , Ethanol/administration & dosage , Femoral Artery/abnormalities , Femoral Vein/abnormalities , Follow-Up Studies , Injections , Oleic Acids/administration & dosage , Polidocanol , Polyethylene Glycols/administration & dosage , Rats , Rats, Wistar , Solvents/administration & dosage , Tissue Adhesives , Treatment Outcome
16.
Neurology ; 78(20): 1601-7, 2012 May 15.
Article in English | MEDLINE | ID: mdl-22551731

ABSTRACT

OBJECTIVE: To describe 16 patients with a coincidence of 2 rare diseases: aquaporin-4 antibody (AQP4-Ab)-mediated neuromyelitis optica spectrum disorder (AQP4-NMOSD) and acetylcholine receptor antibody (AChR-Ab)-mediated myasthenia gravis (AChR-MG). METHODS: The clinical details and antibody results of 16 patients with AChR-MG and AQP4-NMOSD were analyzed retrospectively. RESULTS: All had early-onset AChR-MG, the majority with mild generalized disease, and a high proportion achieved remission. Fifteen were female; 11 were Caucasian. In 14/16, the MG preceded NMOSD (median interval: 16 years) and 11 of these had had a thymectomy although 1 only after NMOSD onset. In 4/5 patients tested, AQP4-Abs were detectable between 4 and 16 years prior to disease onset, including 2 patients with detectable AQP4-Abs prior to thymectomy. AChR-Abs decreased and the AQP4-Ab levels increased over time in concordance with the relevant disease. AChR-Abs were detectable at NMOSD onset in the one sample available from 1 of the 2 patients with NMOSD before MG. CONCLUSIONS: Although both conditions are rare, the association of MG and NMOSD occurs much more frequently than by chance and the MG appears to follow a benign course. AChR-Abs or AQP4-Abs may be present years before onset of the relevant disease and the antibody titers against AQP4 and AChR tend to change in opposite directions. Although most cases had MG prior to NMOSD onset, and had undergone thymectomy, NMOSD can occur first and in patients who have not had their thymus removed.


Subject(s)
Myasthenia Gravis/complications , Myasthenia Gravis/therapy , Neuromyelitis Optica/complications , Neuromyelitis Optica/therapy , Adolescent , Adult , Age of Onset , Antibodies , Aquaporin 4/immunology , Autoantibodies , Brain/pathology , Child , Female , Humans , Longitudinal Studies , Magnetic Resonance Imaging , Male , Middle Aged , Myasthenia Gravis/blood , Myasthenia Gravis/immunology , Neuromyelitis Optica/blood , Neuromyelitis Optica/immunology , Receptors, Cholinergic/immunology , Retrospective Studies , Thymectomy , Young Adult
17.
Phys Rev Lett ; 109(23): 235306, 2012 Dec 07.
Article in English | MEDLINE | ID: mdl-23368220

ABSTRACT

We report clear experimental signatures of the theoretically unexpected gas-liquid transition in the first three monolayer systems of (3)He adsorbed on graphite. The transition is inferred from the linear density dependence of the gamma coefficient of the heat capacity measured in the degenerate region (2≤T≤80 mK) below a critical liquid density (ρ(c0)). Surprisingly, the measured ρ(c0) values (0.6-0.9 nm(-2)) are nearly the same for all these layers in spite of their quite different environments. We conclude that the ground state of (3)He in strictly two dimensions is not a dilute quantum gas but a self-bound quantum liquid with the lowest density ever found.

18.
Clin Microbiol Infect ; 17(12): 1792-7, 2011 Dec.
Article in English | MEDLINE | ID: mdl-21595790

ABSTRACT

The microscopic observation drug susceptibility assay (MODS) was evaluated to determine susceptibility to pyrazinamide in Mycobacterium tuberculosis, and compared with the broth microdilution method (BMM), absolute concentration method (ACM), and pyrazinamidase (PZase) determination. We tested 34 M. tuberculosis clinical isolates (24 sensitive and eight resistant to pyrazinamide) and the control strains M. tuberculosis H37Rv (ATCC 27294) and Mycobacterium bovis AN5. The MODS, BMM, ACM and PZase determination provided results in average times of 6, 18, 28 and 7 days, respectively. All methods showed excellent sensitivity and specificity (p <0.05). Of the methods studied, the MODS proved to be faster, efficient, inexpensive, and easy to perform. However, additional studies evaluating the MODS in differentiating pyrazinamide-resistant and pyrazinamide-susceptible M. tuberculosis must be conducted with a larger number of clinical isolates.


Subject(s)
Antitubercular Agents/pharmacology , Drug Resistance, Bacterial , Microscopy/methods , Mycobacterium tuberculosis/drug effects , Pyrazinamide/pharmacology , Humans , Microbial Sensitivity Tests/methods , Mycobacterium bovis/drug effects , Mycobacterium tuberculosis/isolation & purification , Sensitivity and Specificity , Time Factors , Tuberculosis/microbiology
19.
Article in English | MEDLINE | ID: mdl-19091782

ABSTRACT

Bioassay-guided fractionation of the chloroform extract of Byrsonima fagifolia leaves led to the isolation of active antitubercular compounds alkane dotriacontane (Minimal Inhibitory Concentration-MIC, 62.5 µg mL(-1)), triterpenoids as bassic acid (MIC = 2.5 µg mL(-1)), α-amyrin acetate (MIC = 62.5 µg mL(-1)), a mixture of lupeol, α- and ß-amyrin (MIC = 31.5 µg mL(-1)) and a mixture of lupeol, and acetates of α- and ß-amyrin (MIC = 31.5 µg mL(-1)). The antimycobacterial activity was determined by the Microplate Alamar Blue Assay (MABA) and the structures of promising compounds were determined by spectroscopic analysis. This investigation constitutes the first report of a chemical and antitubercular study of apolar compounds from B. fagifolia Niedenzu (IK).

20.
Zoonoses Public Health ; 57(6): 382-7, 2010 Sep.
Article in English | MEDLINE | ID: mdl-19538453

ABSTRACT

With the evidence showing the protection variability of bacille Calmette-Guérin, new potential vaccines for tuberculosis have been tested around the world. One of the general concerns in tuberculosis vaccine development is the possibility of priming the host immune system with prior exposure to environmental mycobacteria antigens, which can change the efficacy of subsequent vaccination. As there is a great homology between the species from Mycobacterium genera, the previous contact of experimental animals with environmental mycobacteria could sensitize the mice and, in this way, could influence subsequent vaccine research. The aim of our study was to investigate critical points in an animal facility to search for environmental mycobacteria that eventually could be in direct or indirect contact with the experimental animals. Samples were collected from surfaces of walls, floor, animal cages and shelves and analysed using the Ogawa-Kudoh decontamination method. Samples of drinking water, food and sawdust were collected for analysis by the NALC/NaOH decontamination method. Also, the samples were cultivated directly in broth medium, without any method for decontamination. After decontamination methods, we observed bacterial colony growth in 4.31% of the total of samples analysed. These samples were stained with Ziehl-Neelsen and we did not detect any acid-fast bacilli, suggesting that the animal facility analysed is free from contamination by environmental mycobacteria and is not a source of mycobacterial antigens. Furthermore, our study showed a new paradigm in tuberculosis vaccine development: concern about the animal facility environment in terms of immune system priming of experimental animals by nascent bacterial contaminants.


Subject(s)
Decontamination/methods , Environmental Exposure/analysis , Mycobacterium Infections/microbiology , Mycobacterium/isolation & purification , Acetylcysteine , Animals , Antigens, Bacterial , BCG Vaccine/immunology , Biofouling , Brazil , Housing, Animal , Mice , Mycobacterium/immunology , Mycobacterium Infections/immunology , Sodium Hydroxide , Specific Pathogen-Free Organisms , Tuberculosis/immunology , Tuberculosis/prevention & control
SELECTION OF CITATIONS
SEARCH DETAIL
...